Your one-stop shop for everything BIO.
Download the latest flip-books, apps,
free trials, and white papers from our media partners.
Download the onsite Pocket Guide in advance.
Download the 2013 Program Book with speakers as of March 22, 2013.
An overview of what to expect at the 2013 BIO International Convention - programming, attendees, companies, and more. A powerpoint presentation on Slideshare.
2013 Floorplans: BIO Business Forum and BIO Exhibition
Visit the myBIO mobile site. The app is now available in the itunes.
Friends of BIO! Enjoy a free trial of BioCentury products by completing this form--choose between BioCentury, the Bernstein Report on BioBusiness, BioCentury Extra, BioCentury Archives and/or SciBX: Science-Business eXchange.
Enjoy a risk free free trial of BioWorld.
Map Your Business Calendar with BIO Events
Receive a complimentary subscription to PharmaVOICE magazine. See who’s raising their VOICE on the topics and trends that are impacting the life-sciences industry.
Lynn Yoffee, Executive Editor January 2013
How drug development's vanguard is building better therapeutics.
By: Ron Cohen, Punit Dhillon, and Yuichi Iwaki May 2012
In this article, biotech executives address the need for regulations that address the specific needs of biotech and how funding challenges can impact innovation.
PharmaVentures April 2012
An overview of the Emerging Market opportunity including analysis of selected players. The paper also outlines a framework to help companies determine strategies for these regions.
Megan Scudellari March 1, 2012
Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.
By: Kai-Jye Lou January 19, 2012
Enjoy a comprehensive analysis of public-private partnership (PPP) activity worldwide and contrasted it to early stage venture investing during the same period. Highlights include a breakdown of global public-private partnerships by companies and institutions, the emergence of New York as a translational hub, the impact of nongovernmental funding on infectious disease research compared with the more muted VC support of this area, and the high interest of foreign companies in funding research in China.
Gary Boas March 2012
So you came up with this great idea for a medical device for cancer imaging, and even found a way to make it work. Now what? Several researchers involved with coherence imaging technologies discuss the challenges of clinical translation.
Eric Langer January 2012
Responses from 100s of global, biomanufacturers/CMOs in 31 countries, and over 100 vendors to the industry show that technology, and productivity-related investments top the spending and budgets this year.
Pharma's most dynamic sector continues to redefine itself through the adoption of risk-minimizing plant design and construction strategies, use of single-use process equipment, and adoption of such concepts as Quality by Design, exploration of biosimilars and process analytical technology. In this eBook from Pharmaceutical Manufacturing, experts in key areas discuss trends and what they mean for biopharma in facility construction, manufacturing, quality control and compliance, and process control and optimization.
Dimitris Dogramatzis October 13, 2011
Part I of this three-part article focuses on the nature of the biopharmaceutical marketing’s four P’s, the importance of marketing strategy, the conduct of environmental analysis, and maket segmentation.
Cindy H. Dubin, Contributor, Drug Development & Delivery January 2013
NanoSmart Pharmaceuticals is developing next-generation liposomes that bind to areas of necrosis. The platform’s applicability to multiple cancer types can address the underserved, pediatric patient population.
Glyn Edwards Spring 2012
Glyn Edwards of the BioIndustry Association analyses the Strategy for UK Life Sciences, and suggests steps to foster further growth
By: Rachel Duran April 25th, 2011
Getting students excited about STEM education will go a long way in the future of bioscience.
By: Tarun Jain, Bipul Pandey April 1, 2012
The authors discuss the technology and guidance required to achieve good knowledge management in a biopharmaceutical company.